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Molecular genetics analysis of osteogenesis 
imperfecta in clinical practice
Annika Stubbe1, Dragan Primorac2,3,4,5,6,7,8,Wolfgang Höppner1
Osteogenesis imperfecta (OI) is characterized by fractures with minimal or absent trauma, representing a continuum ranging from 
perinatal lethality through individuals with severe skeletal deformities to nearly asymptomatic individuals with mild predisposition 
to fractures. Diagnosis of OI is an interdisciplinary task based on family and/or patient history of fractures combined with character-
istic physical fi ndings. Radiographic examination reveals fractures of varying ages and stages of healing, wormian bones, and osteo-
penia. As there is no defi nitive test for OI, molecular genetic testing by next generation sequencing (NGS) of COL1A1 and COL1A2 and 
up to 12 other genes is essential to confi rm the genetic background. Therefore, we designed a NGS gene panel comprising 12 genes 
involved in OI or severe osteoporosis. Here we report results in a cohort of 11 apparently sporadic young patients with OI, all off spring 
of unaff ected parents, who were referred to orthopaedic surgery at Sv. Katarina Special Hospital (Zabok/Zagreb, Croatia). Ten 
of these 11 patients could be classifi ed genetically. Overall, three genes with diff erent percent relating to the whole cohort were 
 involved: COL1A1 (63.6%), COL1A2 (18.18%) and WNT1 (9.09%).
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INTRODUCTION
Bone fragility with fractures in infancy or childhood has 
been reported in over 100 genetic disorders from skeletal 
dysplasia and inborn errors of metabolism to congenital in-
sensitiveness of pain (1). The most common genetic form of 
bone fragility is osteogenesis imperfecta (OI). The disease is 
phenotypically and genetically heterogeneous and can 
manifest in various phenotypes including perinatal lethality, 
severe and multiple skeletal deformities, severe juvenile os-
teoporosis, as well as mildly aff ected individuals (2-4). De-
spite the direct infl uence on bone structure, it can be ac-
companied by numerous symptoms such as blue sclera, 
deafness, abnormal tooth development, joint hypermobili-
ty, increased risk of hernias, capillary fragility, aneurysms, 
etc. The diagnosis of OI based solely on clinical evaluation 
may be missed (2). Molecular genetics diagnosis is therefore 
instrumental for accurate clinical diagnosis.
Treatment for OI is directed at managing the symptoms. A 
multidisciplinary approach to treatment is essential for chil-
dren and adults. The goal of all treatments for OI is to mini-
mize fractures, enhance independent function, reduce pain, 
support mobility, and promote general health. Medication 
with bisphosphonates, vitamin D and calcium aims at pre-
serving bone mass and strength (3, 4). Physical therapy, frac-
ture care, and orthopedic surgery are approaches for the 
musculoskeletal aspects of OI. In particular, orthopedic sur-
gery including osteotomy, intramedullary rodding is per-
formed to correct bowing of long bones, support stability, 
correct the mechanical axis, and stabilize the spine (5).
Osteogenesis imperfecta has been classifi ed into autoso-
mal dominant and recessive forms. More than 90% of OI 
cases are caused by heterozygous mutations in COL1A1 
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(type 1 collagen α-chain) or COL1A2 (type 2 collagen 
α-chain) and show autosomal dominant inheritance. How-
ever, in the last years, a number of genes responsible for 
both recessive and dominant forms of this condition have 
been described. Currently, 17 distinct types of OI character-
ized on the basis of genotypic features are listed in scientifi c 
databases (Table 1) (6). For complete molecular genetics 
analyses of the COL1A1 and COL1A2 genes, more than 100 
exons have to be analyzed. This is an expensive and time 
consuming task with conventional Sanger sequencing (7, 
8). To be able to cover the complete coding region of the 
COL1A1 and COL1A2 genes, as well as most important other 
OI and severe osteoporosis causing genes in one analytical 
run, we decided to employ next generation sequencing 
(NGS). This new technique combines high performance 
with signifi cantly lower operation cost and processing time. 
Massive parallel sequencing with NGS enables analyzing 
many genes at the same time. Therefore, we designed a 
NGS gene panel comprising 12 genes involved in OI or se-
vere osteoporosis.
Here we report the results in a cohort of 11 apparently spo-
radic young patients with OI, all off spring of unaff ected, non-
related parents, who were referred to orthopedic surgery at 
Sv. Katarina Special Hospital (Zabok/Zagreb, Croatia).
PATIENTS AND METHODS
The molecular genetics analysis preceded orthopedic sur-
gery and established the diagnosis of OI. We utilized the 
IonTorrent PGM next generation platform (Thermo Fisher 
Scientifi c, Walham, MA, USA) in our setting for molecular di-
agnosis of OI. The gene panel was designed with the online 
tool AmpliSeq Designer from Thermo Fisher Scientifi c. Tech-
nical characteristics of the gene panel are shown in Table 2. 
DNA preparation from EDTA-blood was performed with 
Qiagen blood kit (Qiagen, Hilden, Germany) and amplifi ed 
by multiplex polymerase chain reaction. More than 12 pa-
tients can be sequenced together in one analytical run ei-
ther for the same gene panel or for diff erent gene panels. 
Figure 1 shows an example of loading map of a chip (316v2) 
TABLE 1. Genes and phenotypes involved in osteogenesis imperfecta 
(OI) and severe osteoporosis
Phenotype Mode of inheritance
Gene name, symbol 
and MIM-number
Osteogenesis imperfecta (OI) and/or severe osteoporosis
OI Type I, IIa, III, IV AD Type 1 collagen α-chain, COL1A1 
gene, MIM*120150, 
OI Type I, IIa, III, IV AD Type 2 collagen α-chain, COL1A2 
gene, MIM*120160
OI Type IIb 
and Type VII
AD, AR Cartilage associated protein, 
CRTAP gene, MIM*605497
OI Type V AD Interferon-induced 
transmembrane protein 5, IFITM5, 
MIM*614757 
OI Type VI AR Serpin peptidase inhibitor, clade F, 
member 1, SERPINF1 gene, 
MIM*172860
OI Type VIII AR Prolyl 3 hydroxylase 1, P3H1, 
MIM*610342 
OI Type IX AR Peptidyl isomerase B (cyclophin B), 
PPIB, MIM*123841
OI Type X AR Serpin peptidase inhibitor, clade H, 
member 1, SERPINH1, MIM*600943
OI Type XI, including 
Bruck syndrome 1
AR FK506-binding-protein 10, FKBP10 
gene, MIM*607063
Procollagen-lysine, 2-oxoglutarate 
5-diopxygenase 2; PLOD2 gene, 
MIM* 601865
OI Type XII AR Transcription factor SP7, SP7 gene, 
MIM*606633
OI Type XIII AR Bone morphogenic protein 1, 
BMP1, MIM*112264
OI Type XIV AR Transmembrane protein 38B, 
TMEMB38, MIM*611236
OI Type XV AR Wingless-Type MMTV integration 
site family, Member 1, WNT1, 
MIM*164820
OI Type XVI AR Chromome 11p11.2 Deletion 
syndrome, CREB3L1, MIM#616229
OI Type XVII AR Secreted protein, acidic, cysteine-
rich, SPARC gene, MIM182120
X-linked form OI XLD Membrane bound transcription 
factor protease S, site 2, MBTPS2 
gene MIM *300294




AD Low density lipoprotein 














AR Alkaline phosphatase, liver/bone/











endopeptidase homolog X-linked, 
PHEX gene, MIM *300550
Genes in bold are included in the osteogenesis/severe osteoporosis NGS 
gene panel for the fi rst round of sequence analysis. All the other genes 
are included in a NGS gene panel for a second screening round.
TABLE 2. Technical characteristics of the next generation sequencing 
(NGS) panel for osteogenesis imperfecta/severe osteoporosis 
Technical Panel Data Values
Number of genes 12
Panel size 66.32 kb
Primer Pools 2
Total number of exons 213
Total number of amplicons 351
Amplicon lengths approximately 200–250 bp
Covering 97.94%
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used in this study. It serves as a process control and demon-
strates the even distribution of the ion spheres loaded with 
amplifi ed DNA.
For our fi rst round mutation screening panel we included 
12 genes known to cause severe destruction of bone archi-
tecture in newborn, children and young adults. This panel 
includes three genes causing autosomal dominant inheri-
tance OI (COL1A1, COL1A2 and IFITM5), three genes causing 
common recessive forms of OI (CRTAP, LEPRE1 and WNT1) 
and six genes causing severe osteoporosis including the ju-
venile form (PHEX, VDR, CYP27B1, LRP5, ALPL and CASR) (Ta-
ble 3). Bioinformatic analysis was carried out with the soft-
ware module SeqNext (SeqPilot™, JSI, Ettenheim, Baden-
Württemberg, Germany). All NGS results had a very good 
quality. Sequences of insuffi  cient quality were repeated 
with Sanger sequencing.
RESULTS
Mutations in the COL1A1 gene, autosomal dominant 
inheritance of OI
Pathogenic mutations were detected in 10 of 11 patients. 
Seven patients were heterozygous for a pathogenic muta-
tion in the COL1A1 gene (Table 3). In fi ve of these cases (K.A., 
FIGURE 1. A = loading map of a 316v2 chip of the Ion PGM: red indicates the Ion Spheres with bound DNA fragments. Sequence information 
from the individual patients can be distinguished by an individual ‘bar code’ sequence ligated to the PCR products. B, C = two examples of variants 
detected with the software module SeqNext: B = c.1678G>A (p.Gly560Ser) (glycine to serine mutation, patient K.A.) and C = c.2235+1G>A 
(splice site mutation, patient E.L.).
TABLE 3. Patient clinical phenotype, osteogenesis imperfecta (OI) causing mutations and predicted phenotype based on genotype (het: 
heterozygous, hom: homozygous)
Gene Exon/intron Variant
Patient ID Predicted 
phenotype ReferenceE.L. Y.V. M.M. E.S. L.R. S.Y. K.A. A.D. N.L. K.K. M.V.
COL1A1
Intron 1 c.104-441G>T het - - het het hom - het - - - Reduced BMD 21
Exon 25 c.1678G>A (p.Gly560Ser) - - - - - - het - - - - OI type I/IV 13, 15
Intron 32 c.2235+1G>A het - - - - - - - - - - OI type III 13
Exon 33 c.2299G>A (p.Gly767Ser) - - - - het - - - - - - OI type III 16
Exon 43 c.3118G>A (p.Gly1040Ser) - - - het - - - - het - - OI type III/ IV 12, 13, 14
Exon 44 c.3226G>A (p.Gly1076Ser) - het - - - - - - - - - OI type III/ IV 13, 17
Exon 49 c.3835A>T (p.Asn1279Tyr) - - - - - - - - - - het OI type III 18
COL1A2
Exon 19 c.982G>A (p.Gly328Ser) - - het - - - - - - - - OI type III 19
Exon 40 c.2458G>A (p.Gly820Ser) - - - - - - - het - - - OI type III 20
WNT1
Exon 2 c.212T>C (p.Leu71Pro) - - - - - het - - - - - OI type XV -
Exon 3 c.528C>G (p.Phe176Leu) - - - - - het - - - - - OI type XV -
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L.R., E.S., N.L., Y.V.), a glycine residue was mutated to serine in 
the triple helical region. This essential 3-dimensional struc-
ture depends on multiple triplets with the sequence Gly-X-Y 
where X often is hydroxylated lysine and Y hydroxylated 
proline (9). Mutations of glycine are the most common 
pathogenic cause of OI. Two unrelated patients of this 
group carried the same heterozygous mutation (E.S. and 
N.L.), which was published before by several authors (10-
12). The remaining three glycine to serine mutations in the 
triple helical region found in our patients (K.A., L.R, Y.V.) were 
also published before (11-13). All the glycine to serine muta-
tions we found to be related to OI type III, which matched 
with the clinical diagnosis of our expert team.
One patient (E.L.) displayed a heterozygous splice site muta-
tion in position +1 of intron 32 of the COL1A1 gene, which 
leads to a severely compromised protein. Also, this muta-
tion was decribed before with the OI type III (13). For an-
other patient (M.V.), we found a COL1A1 missense mutation 
in the N-terminal part of the pro alpha chain region close to 
a calcium binding site located within in the integrin-C-pro-
peptide interaction region. A mutation at the same codon, 
but with another amino acid exchange has been reported 
before with a phenotype of OI type III (12). 
Mutations in the COL1A2 gene, autosomal dominant 
inheritance of OI
For two patients (M.M., A.D.), the NGS analysis revealed het-
erozygous mutations in the COL1A2 gene. Like in the CO-
L1A1 gene, glycine residues located in the triple helical re-
gion were mutated to serine. Clinically, we classifi ed both 
patients as OI type III, which matches with the correspond-
ing phenotype in the scientifi c literature (13, 14). 
Mutations in the WNT1 gene, autosomal recessive form 
of OI
For one of our 11 patients (S.Y.), we found two heterozygous 
missense mutations in the WNT1 gene. The WNT1 gene en-
codes a signaling protein, which is among others involved 
in bone mineralization. So far, none of these mutations has 
been described in the literature. The online tools MutPred, 
SIFT and PolyPhen 2 classifi ed these mutations as deleteri-
ous. Assuming a compound heterozygous state, the classi-
fi cation would be OI type XV, which correlates with the 
clinical diagnosis of OI type III for our patient.
Variant in the COL1A1 gene
In fi ve patients, we detected the variant c.104-441G>T 
(rs1800012) (E.L., E.S., L.R., S.Y., A.D.). Four patients were het-
erozygous for this transversion mutation, whereas one pa-
tient was homozygous (S.Y.). The frequency of this variant in 
the global population is 9%. It is associated with lower bone 
mineralization (1). The infl uence on the OI phenotype is 
most probably negligible.
Non-classifi ed case
For one of our patients (K.K.), no relevant mutation was de-
tected with our NGS panel. So, this case remains unclassi-
fi ed for the moment. Mutation screening for the remaining 
autosomal recessive genes (Table 1) as a second round is in 
progress. This patient was clinically classifi ed as OI type I, a 
moderate form of OI. 
DISCUSSION
Osteogenesis imperfecta is a disorder of bone formation 
that can be caused by diff erent mutations in several genes 
(22-24). Thorough interdisciplinary diagnostics is necessary 
to explore the possible causes behind each individual case. 
Diff erent pathogenic mechanisms may be involved, includ-
ing aspects of bone metabolism such as bone formation, 
bone resorption, calcium, phosphorous and/or vitamin D 
homeostasis, defective collagen or defects in posttransla-
tional processing of collagen, as well as errors in osteoblast 
diff erentiation and intracellular signaling (25). Primary and 
secondary causes of changes in bone structure have to be 
sorted out. Patients with severe bone deformities and mul-
tiple fractures often require combinations of therapies in-
cluding medication with bisphosphonates, calcium and vi-
tamin D, and extensive surgical treatments including tele-
scope nails to shape, stabilize and strengthen femora and 
lower legs.
Molecular diagnosis of OI or severe osteoporosis causing 
genes does not only confi rm the diagnosis. Greater aware-
ness of the exact genetic profi le of a patient supports the 
introduction of appropriate and timely treatments. In the 
cohort of patients reported here, a team of experienced cli-
nicians diagnosed OI type III in most cases. In all but one 
patient, the genetic test result and the clinical diagnosis 
matched very well. There is only one out of 11 patients with-
out a genetic diagnosis. Screening for mutation in other 
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S A Ž E T A K
Molekularno-genetička analiza osteogenesis imperfecta 
u kliničkoj praksi
Annika Stubbe, Dragan Primorac,Wolfgang Höppner
Osteogenesis imperfecta (OI) je obilježena prijelomima uz minimalnu ili odsutnu traumu i predstavlja kontinuum u rasponu od 
 perinatalne smrtnosti, osobe s teškim skeletnim deformitetima do gotovo asimptomatskih osoba s niskom sklonošću prijelomima. 
Dijagnosticiranje OI je interdisciplinski zadatak koji se temelji na obiteljskoj i/ili bolesnikovoj povijesti prijeloma u kombinaciji sa 
znakovitim fi zičkim nalazima. Radiografsko snimanje otkriva prijelome različite starosti i stadija zaraštanja, Wormove kosti i osteo-
peniju. Kako nema konačnog testa za OI, molekularno genetsko testiranje pomoću next generation sequencing (NGS) gena COL1A1 
i COL1A2 te do 12 drugih gena bitno je za potvrdu genetske podloge. Stoga smo izradili NGS genski panel koji sadrži 12 gena uklju-
čenih u OI ili tešku osteoporozu. Prikazujemo rezultate dobivene u nizu od 11 očito sporadičnih mladih bolesnika s OI, svi potomci 
nezahvaćenih roditelja, koji su bili upućeni na ortopedsku kirurgiju u Specijalnoj bolnici sv. Katarina u Zaboku/Zagrebu. Deset od tih 
11 bolesnika mogli smo genetski klasifi cirati. Sveukupno, uključena su bila tri gena u različitim postocima u našem nizu bolesnika: 
COL1A1 (63,6%), COL1A2 (18,18%) i WNT1 (9,09%).
Ključne riječi: osteogenesis imperfecta; molekularna genetika - analiza
